Cargando…

Performance of Remsima® Monitor Drug Level versus RIDASCREEN IFX Monitoring in therapeutic drug monitoring of infliximab in patients with inflammatory bowel disease: A study of diagnostic accuracy

Therapeutic drug monitoring (TDM) is effective in optimizing the efficacy of infliximab in patients with inflammatory bowel disease (IBD). An affordable way of monitoring is in high demand. This study evaluated the analytical and clinical performances of the newly available Remsima monitor kits and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Joo Hye, Hong, Sung Noh, Kim, Eun Ran, Chang, Dong Kyung, Kim, Young-Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509095/ https://www.ncbi.nlm.nih.gov/pubmed/36197194 http://dx.doi.org/10.1097/MD.0000000000030683

Ejemplares similares

Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
por: Zachou, Maria, et al.
Publicado: (2022)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic
por: McGoran, John, et al.
Publicado: (2021)

Physicochemical characterization of Remsima®
por: Jung, Soon Kwan, et al.
Publicado: (2014)

The Budget Impact of Biosimilar Infliximab (Remsima(®)) for the Treatment of Autoimmune Diseases in Five European Countries
por: Jha, Ashok, et al.
Publicado: (2015)

Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
por: Kolho, Kaija-Leena
Publicado: (2021)

The DNA60IFX contest
por: Schatz, Michael C, et al.
Publicado: (2013)

Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis
por: Gordon, Benjamin L., et al.
Publicado: (2023)

Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment
por: Anderson, Ginger, et al.
Publicado: (2022)

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021)

Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels
por: Pérez, Irene, et al.
Publicado: (2018)

Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction
por: Normatov, Inessa, et al.
Publicado: (2021)

Therapeutic drug monitoring in inflammatory bowel disease
por: Kopylov, Uri, et al.
Publicado: (2014)

Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring
por: Syed, Nauroz, et al.
Publicado: (2020)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Therapeutic drug monitoring in inflammatory bowel disease treatments
por: Wang, Meng-Yao, et al.
Publicado: (2022)

Updates in therapeutic drug monitoring in inflammatory bowel disease
por: Lodhia, Nilesh, et al.
Publicado: (2022)

788. Therapeutic Drug Monitoring for Pyrazinamide During Tuberculosis Treatment: What Is the Diagnostic Accuracy?
por: Anderson, Ginger, et al.
Publicado: (2018)

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA
por: Toja-Camba, Francisco José, et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics
por: Little, Robert D., et al.
Publicado: (2022)

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
por: Lee, Changsoo, et al.
Publicado: (2017)

Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
por: Martins, Camilla de Almeida, et al.
Publicado: (2022)

Therapeutic drug monitoring for biological medications in inflammatory bowel disease
por: Cogan, Rachel C., et al.
Publicado: (2022)

Accuracy of Therapeutic Drug Monitoring of Teicoplanin at the Onset of Febrile Neutropenia
por: Takigawa, Masaki, et al.
Publicado: (2023)

Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction—A Prospective Trial
por: Garcia, Karoline Soares, et al.
Publicado: (2023)

A203 EARLY PROACTIVE DRUG MONITORING STRATEGY OF INFLIXIMAB AS MONOTHERAPY FOR INFLAMMATORY BOWEL DISEASE IN PAEDIATRIC PATIENTS IS ASSOCIATED WITH GOOD SUSTAINED CLINICAL REMISSION
por: Girard, C, et al.
Publicado: (2023)

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial
por: Cohen, Stanley B., et al.
Publicado: (2020)

Diagnostic and medical needs for therapeutic drug monitoring of antibiotics
por: Mabilat, Claude, et al.
Publicado: (2019)

Is Therapeutic Drug Monitoring of Teicoplanin Useful?
por: Kim, Shin-Woo
Publicado: (2014)

Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia
por: Cai, Chenwen, et al.
Publicado: (2022)

Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments
por: Lee, Scott D., et al.
Publicado: (2021)

The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience
por: Mitchell, Robert A., et al.
Publicado: (2016)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
por: Eun, Chang Soo
Publicado: (2017)

Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments
por: Shimizu, Toshimasa, et al.
Publicado: (2020)

Analytical Performance of the RIDASCREEN(®) Hantavirus Puumala IgG/IgM ELISA Assay
por: Depypere, Melissa, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Posaconazole: an Update
por: Dekkers, Bart G. J., et al.
Publicado: (2016)

Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease
por: Simsek, Melek, et al.
Publicado: (2017)

Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease
por: Kapoor, Akshay, et al.
Publicado: (2021)

Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place
por: Truta, Brindusa
Publicado: (2022)

Microfluidic Thermal Flowmeters for Drug Injection Monitoring
por: Doh, Il, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5konnapos7bovmmuk3rf0mmvo3